Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

108
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
108
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Vaccine Production01:23

Vaccine Production

158
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
158

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and Pharmacodynamics of (Val)Ganciclovir in Infants with Congenital Cytomegalovirus.

medRxiv : the preprint server for health sciences·2026
Same author

Why do we have a vaccine for measles, but not cytomegalovirus (CMV)?

PLoS pathogens·2026
Same author

The Management of Congenital Cytomegalovirus Infection in an Era of Universal Newborn CMV Screening.

Reviews in medical virology·2026
Same author

A Vaccine to Prevent Congenital Cytomegalovirus: Where Do We Go Next?

JAMA pediatrics·2026
Same author

Recent insights into the immunobiology of congenital cytomegalovirus infection.

Current opinion in physiology·2026
Same author

Multistate Infant Botulism Outbreak Associated with Powdered Infant Formula.

NEJM evidence·2026
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

14.3K

Priorities for CMV vaccine development.

Philip R Krause1, Stephanie R Bialek2, Suresh B Boppana3

  • 1Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, United States.

Vaccine
|October 17, 2013
PubMed
Summary
This summary is machine-generated.

Developing vaccines against cytomegalovirus (CMV) is crucial for preventing congenital CMV disease and serious illness in immunocompromised individuals. Research priorities include optimal vaccine use, clinical trial design, and further studies for CMV vaccine advancement.

Keywords:
Clinical trial endpointsCongenital CMVCytomegalovirusMeeting reportViruses

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.0K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

18.4K

Related Experiment Videos

Last Updated: May 6, 2026

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
05:53

Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates

Published on: July 6, 2013

14.3K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.0K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

18.4K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Cytomegalovirus (CMV) causes congenital CMV (cCMV) disease and severe illness in immunocompromised populations.
  • Current vaccine development focuses on preventing cCMV disease and CMV-related complications in transplant recipients.

Purpose of the Study:

  • To address priorities for cytomegalovirus (CMV) vaccine development.
  • To discuss optimal vaccine strategies, clinical trial designs, and necessary future research.
  • To outline potential endpoints for CMV vaccine efficacy trials in different populations.

Main Methods:

  • Multidisciplinary meeting to discuss CMV vaccine development priorities.
  • Review of potential vaccine administration strategies (universal childhood, adolescent/adult women).
  • Analysis of appropriate clinical trial endpoints for preventing cCMV infection, CMV disease in stem cell transplant recipients, and CMV-associated disease in solid organ transplant patients.

Main Results:

  • A universal childhood CMV vaccine could reduce cCMV disease by limiting transmission.
  • Vaccinating adolescents or women before pregnancy can prevent cCMV disease.
  • Clinical trial endpoints need adaptation: cCMV infection for maternal-fetal transmission, viremia for stem cell transplant recipients, and CMV disease for solid organ transplant patients.

Conclusions:

  • Further research is essential for CMV vaccine development, including understanding transmission, reactivation vs. reinfection, predictors of sequelae, and immune correlates of protection.
  • Identifying immune correlates and developing validated assays (e.g., antibody avidity) are critical for establishing vaccine efficacy.
  • Strategic vaccine approaches and tailored clinical trial designs are necessary to combat CMV infections effectively.